Literature DB >> 9439758

Human tumor antigens recognized by T-cells.

Y Kawakami1, S A Rosenberg.   

Abstract

T-cells play an important role in in vivo tumor rejection in many animal tumor models and in human melanoma. Many human tumor antigens recognized by autologous T-cells have now been identified. These are found to be nonmutated and mutated peptides derived from various self proteins as well as viral proteins. A variety of mechanisms involved in generating these T-cell epitopes on growing cancers have also been identified. However, the role of these identified antigens remains to be evaluated. Passive or active immunotherapies using these identified tumor antigens are being conducted in many institutions. The results obtained from these clinical trials may give us better insight into the role of T-cell responses to each antigen in tumor rejection as well as the development of new antigen-specific immunotherapies for patients with cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9439758     DOI: 10.1007/BF02786397

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   4.505


  134 in total

Review 1.  T-cell recognition of self peptides as tumor rejection antigens.

Authors:  Y Kawakami; S A Rosenberg
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

2.  Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3.

Authors:  M Marchand; P Weynants; E Rankin; F Arienti; F Belli; G Parmiani; N Cascinelli; A Bourlond; R Vanwijck; Y Humblet
Journal:  Int J Cancer       Date:  1995-12-11       Impact factor: 7.396

3.  Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells.

Authors:  V Tsai; S Southwood; J Sidney; K Sakaguchi; Y Kawakami; E Appella; A Sette; E Celis
Journal:  J Immunol       Date:  1997-02-15       Impact factor: 5.422

4.  A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma.

Authors:  J S Goydos; E Elder; T L Whiteside; O J Finn; M T Lotze
Journal:  J Surg Res       Date:  1996-06       Impact factor: 2.192

5.  Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts.

Authors:  S K Nair; D Snyder; B T Rouse; E Gilboa
Journal:  Int J Cancer       Date:  1997-03-17       Impact factor: 7.396

6.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.

Authors:  T Wölfel; M Hauer; J Schneider; M Serrano; C Wölfel; E Klehmann-Hieb; E De Plaen; T Hankeln; K H Meyer zum Büschenfelde; D Beach
Journal:  Science       Date:  1995-09-01       Impact factor: 47.728

7.  Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.

Authors:  D Boczkowski; S K Nair; D Snyder; E Gilboa
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

8.  Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).

Authors:  D J Loftus; C Castelli; T M Clay; P Squarcina; F M Marincola; M I Nishimura; G Parmiani; E Appella; L Rivoltini
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

9.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.

Authors:  B Fisk; T L Blevins; J T Wharton; C G Ioannides
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

10.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

Authors:  L Zitvogel; J I Mayordomo; T Tjandrawan; A B DeLeo; M R Clarke; M T Lotze; W J Storkus
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  19 in total

Review 1.  Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy.

Authors:  T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

2.  Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

Authors:  Daisuke Sugiyama; Hiroyoshi Nishikawa; Yuka Maeda; Megumi Nishioka; Atsushi Tanemura; Ichiro Katayama; Sachiko Ezoe; Yuzuru Kanakura; Eiichi Sato; Yasuo Fukumori; Julia Karbach; Elke Jäger; Shimon Sakaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

Review 3.  Cancer immunotherapy comes of age.

Authors:  Suzanne L Topalian; George J Weiner; Drew M Pardoll
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

Review 4.  Immune microenvironments in solid tumors: new targets for therapy.

Authors:  Stephen L Shiao; A Preethi Ganesan; Hope S Rugo; Lisa M Coussens
Journal:  Genes Dev       Date:  2011-12-15       Impact factor: 11.361

5.  IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells.

Authors:  Osamu Imataki; Sascha Ansén; Makito Tanaka; Marcus O Butler; Alla Berezovskaya; Matthew I Milstein; Kiyotaka Kuzushima; Lee M Nadler; Naoto Hirano
Journal:  J Immunol       Date:  2012-01-11       Impact factor: 5.422

6.  Serum anti-BPAG1 auto-antibody is a novel marker for human melanoma.

Authors:  Takashi Shimbo; Atsushi Tanemura; Takehiko Yamazaki; Katsuto Tamai; Ichiro Katayama; Yasufumi Kaneda
Journal:  PLoS One       Date:  2010-05-10       Impact factor: 3.240

Review 7.  The optimization of helper T lymphocyte (HTL) function in vaccine development.

Authors:  J Alexander; J Fikes; S Hoffman; E Franke; J Sacci; E Appella; F V Chisari; L G Guidotti; R W Chesnut; B Livingston; A Sette
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

Review 8.  Allogeneic stem cell transplantation for the treatment of advanced solid tumors.

Authors:  Marco Bregni; Massimo Bernardi; Fabio Ciceri; Jacopo Peccatori
Journal:  Springer Semin Immunopathol       Date:  2004-09-11

9.  Profiling humoral immune responses to P. falciparum infection with protein microarrays.

Authors:  Denise L Doolan; Yunxiang Mu; Berkay Unal; Suman Sundaresh; Siddiqua Hirst; Conrad Valdez; Arlo Randall; Douglas Molina; Xiaowu Liang; Daniel A Freilich; J Aggrey Oloo; Peter L Blair; Joao C Aguiar; Pierre Baldi; D Huw Davies; Philip L Felgner
Journal:  Proteomics       Date:  2008-11       Impact factor: 3.984

10.  T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease.

Authors:  Christoph Bergmann; Laura Strauss; Yun Wang; Miroslaw J Szczepanski; Stephan Lang; Jonas T Johnson; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.